1. 793PDPreliminary results from TRITON2: A phase II study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterations. (23rd October 2018) Authors: Abida, W; Bryce, A H; Vogelzang, N J; Amato, R J; Percent, I; Shapiro, J D; McDermott, R; Hussain, A; Patnaik, A; Petrylak, D; Ryan, C J; Stanton, T; Zhang, J; Simmons, A D; Despain, D; Collins, M; Golsorskhi, T; Scher, H I; Chowdhury, S Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. LBA54ENTRATA: Randomized, double-blind, phase II study of telaglenastat (tela; CB-839) + everolimus (E) vs placebo (pbo) + E in patients (pts) with advanced/metastatic renal cell carcinoma (mRCC). (1st October 2019) Authors: Motzer, R J; Lee, C-H; Emamekhoo, H; Matrana, M; Percent, I; Hsieh, J J; Hussain, A; Vaishampayan, U N; Graham, R; Liu, S; McCune, S; Shaheen, M; Parmar, H; Shen, Y; Whiting, S H; Tannir, N M Journal: Annals of oncology Issue: Volume 30(2019)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 206 PRETARGET® RADIOIMMUNOTHERAPY (RIT) WITH A FUSION PROTEIN: PHARMACOKINETIC RESULTS FROM A DOSE OPTIMIZATION STUDY. (1st January 2004) Authors: Forero-Torres, A; Shen, S; LoBuglio, A; Percent, I; Besch, S; Breitz, H; Sims, R; Meredith, R Journal: Journal of investigative medicine Issue: Volume 52(2004)Supplement 1 Page Start: S293 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗